Palvella Therapeutics, Inc. PVLA

PVLA Company Overview

Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare and serious genetic dermatologic diseases with high unmet medical need. The company operates within the biotechnology and pharmaceutical industries, with a specific emphasis on skin disorders where existing treatment options are limited or ineffective.

Palvella’s core strategy centers on advancing targeted, topical therapies designed to modulate disease-driving biological pathways directly in the skin while minimizing systemic exposure. The company was founded in 2021 and became publicly listed in 2024. Its evolution has been driven by the in-licensing and internal development of a proprietary topical formulation platform intended for chronic, genetically driven skin conditions, positioning the company within the rare disease dermatology segment.